Drugs for Gastrointestinal Diseases Practice Questions

Q: Interaction of histamine with H2 receptor in parietal cells results in which of the following?

Increase in intracellular cAMP production. ### Explanation The secretion of gastric acid by parietal cells is regulated by three primary secretagogues: **Histamine, Acetylcholine (ACh), and Gastrin.** **Why Option B is Correct:** Histamine acts on **H2 receptors**, which are **G-protein coupled receptors (GPCRs)** linked to the **Gs (stimulatory)** protein. When histamine binds to the H2 receptor, it activates the enzyme **adenylyl cyclase**, which converts ATP into **cyclic AMP (cAMP)**. Increased intracellular cAMP then activates Protein Kinase A (PKA), which stimulates the **H+/K+ ATPase pump** (the proton pump) to secrete gastric acid into the lumen. **Why Other Options are Incorrect:** * **Options C and D:** These describe the mechanism of **Acetylcholine (M3 receptors)** and **Gastrin (CCK2 receptors)**. Both M3 and CCK2 receptors are linked to **Gq proteins**, which activate the **IP3-DAG pathway**, leading to an increase in **intracellular calcium (Ca2+)**. While this also stimulates the proton pump, it is distinct from the H2-mediated cAMP pathway. * **Option A:** Intracellular Na+ concentration is not the primary second messenger for acid secretion. The final step involves the exchange of H+ for K+, not Na+. **High-Yield Clinical Pearls for NEET-PG:** * **Synergism:** Histamine, Gastrin, and ACh show potentiation; blocking one (e.g., with H2 blockers) significantly reduces the acid-stimulating effect of the others. * **H2 Blockers (e.g., Cimetidine, Ranitidine):** Competitive antagonists that specifically inhibit the cAMP-dependent pathway. * **Proton Pump Inhibitors (PPIs):** These are the "final common pathway" inhibitors, acting downstream of both cAMP and Ca2+ pathways. * **Prostaglandins (PGE2/PGI2):** Act on EP3 receptors linked to **Gi (inhibitory)** proteins, which *decrease* cAMP and inhibit acid secretion.

Q: What is the mechanism of action of Orlistat?

Intestinal lipase inhibitor. **Mechanism of Action: Orlistat** **Correct Answer: B. Intestinal lipase inhibitor** Orlistat is a potent, reversible inhibitor of **gastric and pancreatic lipases**. These enzymes are essential for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. Orlistat works locally in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the lipase enzymes. This prevents the absorption of approximately **30% of dietary fat**, which is instead excreted in the feces, leading to a caloric deficit and weight loss. **Analysis of Incorrect Options:** * **Option A (Central reuptake inhibitor of NE and Serotonin):** This describes the mechanism of **Sibutramine**, an older anti-obesity drug withdrawn globally due to increased cardiovascular risks (MI and stroke). * **Option C (Central reuptake facilitator of serotonin):** This refers to **Tianeptine**, an atypical antidepressant. It is not used for weight management. * **Option D (Intestinal amylase inhibitor):** Amylase inhibitors (like Acarbose) prevent the breakdown of starch into glucose and are used primarily in Type 2 Diabetes Mellitus, not as primary anti-obesity agents. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effects are GI-related: **steatorrhea** (oily spotting), flatus with discharge, and fecal urgency. * **Vitamin Deficiency:** Long-term use can lead to a deficiency of **fat-soluble vitamins (A, D, E, K)**. Patients are usually advised to take a multivitamin supplement 2 hours before or after the dose. * **Pharmacokinetics:** It has negligible systemic absorption; its action is almost entirely local within the GI tract. * **Indication:** It is FDA-approved for long-term obesity management in patients with a BMI ≥30 kg/m² (or ≥27 kg/m² with comorbidities).

Q: Misoprostol, a prostaglandin analogue, is useful as:

Anti-ulcer. **Explanation:** **Misoprostol** is a synthetic **Prostaglandin E1 (PGE1) analogue**. Its primary therapeutic use in the gastrointestinal system is as an **anti-ulcer** agent. **1. Why "Anti-ulcer" is correct:** Misoprostol acts on the parietal cells of the stomach to inhibit gastric acid secretion. More importantly, it possesses **cytoprotective properties** by increasing the secretion of mucus and bicarbonate and improving mucosal blood flow. It is specifically indicated for the **prevention of NSAID-induced gastric ulcers**, as NSAIDs inhibit endogenous prostaglandin synthesis. **2. Why the other options are incorrect:** * **Uterine relaxant:** Incorrect. Misoprostol actually causes **uterine contractions** and cervical ripening. It is used clinically for medical abortion (in combination with Mifepristone) and the induction of labor. * **Bronchodilator:** Incorrect. While some prostaglandins (like PGE2) can cause bronchodilation, Misoprostol is not used for this purpose. PGE2 and PGF2α can actually cause bronchoconstriction in sensitive individuals. * **Vasodilator:** Incorrect. While PGE1 (Alprostadil) is a potent vasodilator used in peripheral vascular disease or to keep the ductus arteriosus open, Misoprostol is not used clinically for its systemic vascular effects. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Misoprostol is the drug of choice for preventing ulcers in patients requiring long-term NSAID therapy. * **Contraindication:** It is strictly **contraindicated in pregnancy** (Category X) due to its oxytocic (abortifacient) properties. * **Side Effects:** The most common side effect is **diarrhea** (due to increased intestinal motility) and abdominal cramps. * **Comparison:** Unlike Proton Pump Inhibitors (PPIs) which only suppress acid, Misoprostol actively replaces the protective prostaglandin barrier.

Q: Metoclopramide acts to achieve which of the following?

Increase gastric emptying. Metoclopramide is a potent **prokinetic agent** and a substituted benzamide [2]. Its primary mechanism of action involves **D2 receptor antagonism** and **5-HT4 receptor agonism**. By blocking inhibitory dopamine receptors and stimulating serotonin receptors in the enteric nervous system, it enhances the release of acetylcholine [1]. This leads to increased gastric tone, improved antral contractions, and relaxation of the pyloric sphincter, which collectively **increase gastric emptying** [2].**Analysis of Options:** * **Option A (Incorrect):** Metoclopramide actually **increases** lower esophageal sphincter (LES) pressure. This makes it clinically useful in managing Gastroesophageal Reflux Disease (GERD) by preventing the backflow of acid.* **Option B (Incorrect):** It **increases** (accelerates) transit through the small intestine. Prokinetics are designed to move luminal contents forward more rapidly.* **Option C (Incorrect):** Metoclopramide is a powerful **anti-emetic**, not an emetic [2]. It acts centrally by blocking D2 receptors in the Chemoreceptor Trigger Zone (CTZ) of the medulla.**High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** It is the preferred agent for **Diabetic Gastroparesis** [2].* **Side Effects:** Due to its D2 blocking property in the CNS, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and Parkinsonism-like symptoms. It also causes **hyperprolactinemia** (leading to galactorrhea/gynecomastia).* **Contraindication:** It must never be used in cases of **mechanical intestinal obstruction**, as increasing motility against an obstruction can lead to perforation.

Q: Which of the following is not used in the treatment of upper gastrointestinal bleeding?

Desmopressin. ### Explanation The management of upper gastrointestinal bleeding (UGIB) focuses on acid suppression and reducing portal pressure. **Desmopressin (dDAVP)** is the correct answer because it is not used for UGIB; it is a synthetic analog of ADH used primarily for Diabetes Insipidus, nocturnal enuresis, and bleeding disorders like von Willebrand disease and Hemophilia A (by increasing Factor VIII and vWF levels). **Why the other options are used:** * **Pantoprazole (Option A):** Proton Pump Inhibitors (PPIs) are the mainstay of treatment. In non-variceal UGIB (e.g., peptic ulcers), high-dose IV PPIs stabilize the blood clot by maintaining a gastric pH >6, as pepsin (which dissolves clots) is inactivated at higher pH levels. * **Terlipressin (Option C):** This is a long-acting analog of vasopressin and the drug of choice for **acute variceal bleeding**. It acts on $V_1$ receptors to cause splanchnic vasoconstriction, thereby reducing portal venous pressure and stopping the bleed. * **Octreotide (Option D):** A synthetic somatostatin analog. it inhibits the release of vasodilator hormones (like glucagon), leading to indirect splanchnic vasoconstriction. It is frequently used as an adjunct to endoscopic therapy in variceal hemorrhage. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Variceal Bleed:** Terlipressin (improves survival). * **Most potent acid suppressant:** PPIs (Pantoprazole/Esomeprazole). * **Somatostatin vs. Octreotide:** Octreotide is preferred due to a longer half-life. * **Desmopressin Side Effect:** Hyponatremia (due to water retention via $V_2$ receptors).

Q: Erythromycin is given in intestinal hypomotility because:

It binds to motilin receptors. **Explanation:** **Mechanism of Action (Why D is correct):** Erythromycin, a macrolide antibiotic, acts as a **prokinetic agent** by mimicking the action of the endogenous peptide hormone **motilin**. It acts as a non-peptide motilin receptor agonist. These receptors are primarily located on the smooth muscles of the gastrointestinal tract (stomach and duodenum). Binding to these receptors triggers **Migrating Motor Complexes (MMCs)**, which stimulate gastric emptying and intestinal motility. **Analysis of Incorrect Options:** * **Options A & B:** While Erythromycin is an antibiotic that affects bacterial counts, its prokinetic effect is independent of its antimicrobial properties. In the context of intestinal hypomotility, the therapeutic benefit is mechanical (motility) rather than microbiological. * **Option C:** Erythromycin does not have a direct clinical mechanism involving the binding of adenylyl cyclase to treat hypomotility. Prokinetic action is mediated through calcium signaling and motilin pathways, not primarily through the cAMP/adenylyl cyclase system. **Clinical Pearls for NEET-PG:** * **Indications:** It is the drug of choice for **Diabetic Gastroparesis** and is also used in intestinal pseudo-obstruction (Ogilvie’s syndrome). * **Dose:** The prokinetic effect occurs at **lower doses** (e.g., 40–250 mg) than those required for antimicrobial activity. * **Tachyphylaxis:** A major limitation of using Erythromycin as a prokinetic is the rapid development of tolerance (tachyphylaxis) due to down-regulation of motilin receptors. * **Side Effects:** The most common side effect is abdominal cramping/diarrhea, which is essentially an extension of its prokinetic pharmacological action.

Q: Misoprostol is an analogue of which prostaglandin?

PGE1. **Explanation:** **Misoprostol** is a synthetic **PGE1 (Prostaglandin E1) analogue** [1]. It is primarily used in gastroenterology for its cytoprotective properties [2]. It acts on the parietal cells of the stomach to inhibit gastric acid secretion and stimulates the secretion of mucus and bicarbonate, thereby protecting the mucosal lining [2]. **Why PGE1 is correct:** Misoprostol is chemically derived from PGE1 [1]. Its primary clinical indication in the GI tract is the **prevention of NSAID-induced gastric ulcers**, as NSAIDs inhibit endogenous prostaglandin synthesis [2]. **Analysis of Incorrect Options:** * **PGE2 (Dinoprostone):** While PGE2 also has cytoprotective effects in the stomach, Misoprostol is specifically a PGE1 analogue. Dinoprostone is used clinically for cervical ripening and induction of labor [1]. * **PGF2α (Dinoprost/Latanoprost):** PGF2α analogues are primarily used in ophthalmology to reduce intraocular pressure (e.g., Latanoprost) or in obstetrics for postpartum hemorrhage (e.g., Carboprost) [1]. * **PGI2 (Prostacyclin/Epoprostenol):** PGI2 is a potent vasodilator and inhibitor of platelet aggregation. Its analogues (e.g., Epoprostenol, Iloprost) are used to treat pulmonary arterial hypertension [1]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Obstetric Use:** Due to its potent uterine contracting properties, Misoprostol is used for medical abortion (in combination with Mifepristone), induction of labor, and management of postpartum hemorrhage (PPH) [1]. 2. **Contraindication:** It is strictly **contraindicated in pregnancy** (Category X) unless used for legal termination, as it is highly teratogenic and can cause uterine rupture. 3. **Side Effects:** The most common side effect is **diarrhea** and abdominal cramps [2]. 4. **Other PGE1 analogues:** Alprostadil (used for maintaining ductus arteriosus patency and erectile dysfunction) [1].

Q: Ursodiol reduces the size of common bile duct gallstones by which mechanism?

Slowly dissolving cholesterol from the stone. **Explanation:** **Mechanism of Action (Why D is correct):** Ursodiol (Ursodeoxycholic acid) is a naturally occurring bile acid. It reduces the size of gallstones primarily by **decreasing the cholesterol saturation index** of bile. It achieves this by: 1. Inhibiting the intestinal absorption of cholesterol. 2. Suppressing hepatic cholesterol synthesis and secretion into the bile. By creating a "cholesterol-unsaturated" environment, Ursodiol promotes the **gradual solubilization (dissolution)** of cholesterol from the surface of the stone into the bile. **Analysis of Incorrect Options:** * **Option A:** Ursodiol does not decrease the overall synthesis of bile; rather, it changes the *composition* of bile, making it richer in hydrophilic bile acids. * **Option B:** Increasing cholesterol content would promote stone formation (lithogenic bile). Ursodiol does the opposite—it **decreases** cholesterol content. * **Option C:** Ursodiol has no effect on calcium. It is ineffective against calcified (radiopaque) stones or pigment stones; it only works on radiolucent **cholesterol stones**. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Small, radiolucent cholesterol gallstones in patients who are poor surgical candidates; Primary Biliary Cholangitis (PBC). * **Prerequisite for use:** The gallbladder must be functional (patent cystic duct) to allow the drug-enriched bile to reach the stones. * **Limitation:** Treatment is slow (months to years) and recurrence is common once the drug is stopped. * **Drug Interaction:** Bile acid sequestrants (Cholestyramine) and Aluminum-containing antacids can bind Ursodiol and decrease its absorption.

Q: Which drug is most effective in inhibiting gastric acid output throughout the day?

Omeprazole. **Explanation:** **1. Why Omeprazole is the Correct Answer:** Omeprazole is a **Proton Pump Inhibitor (PPI)**. It works by irreversibly inhibiting the **H+/K+ ATPase enzyme** (the "proton pump"), which is the final common pathway for gastric acid secretion in parietal cells. Unlike other drugs that block specific receptors (like H2 or M3), PPIs shut down the pump itself. Because the inhibition is irreversible, acid secretion only resumes after new enzyme molecules are synthesized (taking 24–48 hours). This results in the most potent and prolonged suppression of both basal and stimulated gastric acid output throughout the day and night. **2. Why the Other Options are Incorrect:** * **B. Cimetidine:** This is an **H2-receptor antagonist**. While effective, it only blocks the histamine-mediated pathway. Gastrin and Acetylcholine can still stimulate the proton pump, making it less efficacious than PPIs. * **C. Pirenzepine:** This is a selective **M1-muscarinic antagonist**. It reduces vagally stimulated acid secretion but is significantly less potent than H2 blockers or PPIs and is rarely used clinically for this purpose today. * **D. Misoprostol:** This is a **PGE1 analogue**. While it inhibits acid and provides cytoprotection, its primary role is preventing NSAID-induced ulcers. Its acid-inhibitory potency and duration are inferior to Omeprazole. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** PPIs are the DOC for GERD, Peptic Ulcer Disease, and Zollinger-Ellison Syndrome. * **Pharmacokinetics:** PPIs are **prodrugs**, administered as enteric-coated formulations to prevent degradation by stomach acid. They are activated in the acidic environment of the **canaliculi** of parietal cells. * **Timing:** For maximum efficacy, PPIs should be taken **30–60 minutes before a meal** (usually breakfast) to coincide with the maximum activation of proton pumps.

Question 1

Interaction of histamine with H2 receptor in parietal cells results in which of the following?

Accepted Answer

Increase in intracellular cAMP production

Answer

Increase in intracellular Na+ concentration

Answer

Increase in intracellular Ca2+ concentration

Answer

Stimulates IP3-DAG pathway

Question 2

What is the mechanism of action of Orlistat?

Accepted Answer

Intestinal lipase inhibitor

Answer

Central reuptake inhibitor of both norepinephrine and serotonin

Answer

Central reuptake facilitator of serotonin

Answer

Intestinal amylase inhibitor

Question 3

Misoprostol, a prostaglandin analogue, is useful as:

Accepted Answer

Anti-ulcer

Answer

Uterine relaxant

Answer

Bronchodilator

Answer

Vasodilator

Question 4

Metoclopramide acts to achieve which of the following?

Accepted Answer

Increase gastric emptying

Answer

Decrease lower esophageal sphincter pressure

Answer

Decrease transit through the small intestine

Answer

Stimulate vomiting

Question 5

Which of the following is not used in the treatment of upper gastrointestinal bleeding?

Accepted Answer

Desmopressin

Answer

Pantoprazole

Answer

Terlipressin

Answer

Octreotide

Question 6

Erythromycin is given in intestinal hypomotility because:

Accepted Answer

It binds to motilin receptors

Answer

It increases bacterial count

Answer

It decreases bacterial count

Answer

It binds to adenylyl cyclase

Question 7

Misoprostol is an analogue of which prostaglandin?

Accepted Answer

PGE1

Answer

PGE2

Answer

PGF2

Answer

PGI2

Question 8

A patient with diabetic gastroparesis was given erythromycin because of which of the following properties?

Accepted Answer

It imitates motilin

Answer

It increases bacterial count

Answer

It decreases bacterial count

Answer

It binds to adenyl cyclase

Question 9

Ursodiol reduces the size of common bile duct gallstones by which mechanism?

Accepted Answer

Slowly dissolving cholesterol from the stone

Answer

Decreasing the synthesis of bile

Answer

Increasing the cholesterol content in bile

Answer

Chelating Ca2+ out of the stone

Question 10

Which drug is most effective in inhibiting gastric acid output throughout the day?

Accepted Answer

Omeprazole

Answer

Cimetidine

Answer

Pirenzepine

Answer

Misoprostol

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?